Biomerica, Inc. www.biomerica.com is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point of care in home and in physicians offices and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company s products are designed to enhance the health and well being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for diabetes, gastrointestinal disease and esoteric testing.
Quote | Biomerica Inc. (NASDAQ:BMRA)
Last: | $0.6799 |
---|---|
Change Percent: | -4.64% |
Open: | $0.73 |
Close: | $0.713 |
High: | $0.73 |
Low: | $0.66 |
Volume: | 119,637 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Biomerica Inc. (NASDAQ:BMRA)
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in p hysicians prescribing i nFoods more than doubled each quarter over the past 12 months. - Bio...
2024-04-15 00:53:47 ET More on Biomerica Financial information for Biomerica Read the full article on Seeking Alpha For further details see: Biomerica GAAP EPS of -$0.11, revenue of $1M
Message Board Posts | Biomerica Inc. (NASDAQ:BMRA)
Subject | By | Source | When |
---|---|---|---|
Price gaining up | Bigtrader69 | investorshub | 05/17/2023 9:26:45 AM |
Good news recently, we should start to see this one move | RadioSilent | investorshub | 05/17/2023 3:47:39 AM |
The trading | Golden Cross | investorshub | 05/16/2023 3:45:48 PM |
$BMRA Price trading | EggheadEngineer | investorshub | 05/15/2023 9:55:38 PM |
$BMRA Time for a bounce? | ALERTS100%to10000%GAIN | investorshub | 05/15/2023 8:37:45 AM |
News, Short Squeeze, Breakout and More Instantly...
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarter...
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in p hysicians prescribing i nFoods more than doubled each quarter over the past 12 months. - Bio...
Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference in the DDW Irritable Bowel Syn...